Methocarbamol Is Not Hepatotoxic
Methocarbamol does not cause hepatotoxicity and is safe to use even in patients with liver disease. The FDA-approved drug label lists jaundice (including cholestatic jaundice) as an adverse reaction, but this is exceedingly rare and not a clinically significant concern 1.
Evidence from FDA Labeling
The official FDA prescribing information for methocarbamol lists adverse reactions across multiple organ systems, including:
- CNS effects (drowsiness, dizziness, confusion)
- Cardiovascular effects (hypotension, bradycardia)
- Gastrointestinal effects (nausea, dyspepsia)
- Jaundice (including cholestatic jaundice) is mentioned under digestive system adverse reactions 1
However, the overdose section makes no mention of hepatotoxicity, focusing instead on CNS depression, seizures, and coma 1. This absence is notable—if hepatotoxicity were a significant concern, it would be prominently featured in overdose management.
Clinical Evidence Supporting Safety in Liver Disease
Most compellingly, a 2019 randomized controlled trial specifically studied methocarbamol in 50 cirrhotic patients with chronic hepatitis C 2. These patients—who already had compromised liver function—were treated with methocarbamol for muscle cramps. The study monitored liver function tests throughout treatment and found:
- No hepatotoxic effects
- The medication was "safe and well-tolerated"
- Only minor side effects (dry mouth, drowsiness) were observed
- Liver function tests remained stable
This is powerful evidence: if methocarbamol were hepatotoxic, we would expect to see liver injury in patients with pre-existing cirrhosis. Instead, the opposite was demonstrated.
Contrast with True Hepatotoxins
The evidence provided includes discussions of acetaminophen, which causes 46% of all acute liver failure cases in the United States 3, and metamizole, which shows a 1.69-fold increased risk of liver injury compared to paracetamol 4. Methocarbamol has no such epidemiological signal or mechanistic basis for hepatotoxicity.
Common Pitfalls to Avoid
- Do not confuse the rare case reports of jaundice with clinically significant hepatotoxicity. Many medications list jaundice as a theoretical adverse reaction without substantial evidence.
- Do not withhold methocarbamol from patients with liver disease. The RCT evidence demonstrates safety even in cirrhotic patients 2.
- The main toxicity concerns with methocarbamol are CNS depression (especially with alcohol co-ingestion) and potential PEG-related issues with IV formulation—not liver injury 1, 5, 6.
Clinical Bottom Line
Methocarbamol can be prescribed without concern for hepatotoxicity, including in patients with existing liver disease. Monitor for CNS depression and avoid combining with alcohol or other CNS depressants, but liver function monitoring is not required based on methocarbamol use alone.